)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Legend Biotech (LEGN) investor relations material
Legend Biotech Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
CARVYKTI net trade sales reached $524 million in Q3 2025, up 84% year over year, with over 9,000 patients treated globally and expanded access in 14 new international markets.
CARVYKTI remains the leading CAR-T launch, with a 111% CAGR since launch and significant market penetration in both the U.S. and international markets.
FDA and EU approved label updates to include overall survival benefit, making CARVYKTI the only CAR-T in multiple myeloma with this distinction.
Commercial production initiated at the Tech Lane facility in Belgium, supporting global expansion and 246 activated treatment sites worldwide.
Appointment of Carlos Santos as CFO to strengthen financial leadership.
Financial highlights
Q3 2025 total revenues reached $272 million, with collaboration revenue up 84% year over year and IFRS net loss narrowed to $40 million.
Adjusted net loss was $19 million, improved from $42 million year over year; adjusted net loss per share improved to $(0.05) from $(0.11).
Gross margin on net product sales remained steady at 57%.
Cash and cash equivalents, and time deposits totaled approximately $1 billion as of September 30, 2025.
Generated $29 million in operating cash flow during the quarter.
Outlook and guidance
CARVYKTI profitability expected by end of 2025; company-wide profitability targeted for 2026, supported by strong revenue growth and disciplined expense management.
Manufacturing capacity expected to reach 10,000 annualized doses by 2026, with plans to scale to 20,000 doses.
Ongoing expansion of authorized treatment centers, targeting over 160 U.S. sites by 2026 and global expansion into new markets.
Continued focus on expanding into earlier lines of therapy and community settings to drive demand.
Cash position expected to provide financial runway beyond 2026.
CARVYKTI 2025 profitability drivers
Global CARVYKTI supply capacity H1 2026 impact
CARTITUDE-10 strategic importance
How will CARTITUDE-10 impact patient experience?
Community strategy beyond VOA network
Cash allocation strategy post-profitability?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Legend Biotech earnings date
Q4 202511 Mar, 2026
Next Legend Biotech earnings date
Q4 202511 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Legend Biotech Corp is a clinical-stage biopharmaceutical company, focusing on the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. The company's flagship product candidate is LCAR-B38M, a chimeric antigen receptor (CAR) therapy aimed at treating multiple myeloma (MM). Besides, Legend Biotech has developed a diverse portfolio of earlier-stage autologous CAR-T product candidates targeting a variety of cancers, including Non-Hodgkin's Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. The company is headquartered in Somerset, New Jersey, with its shares listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage